A CAR-T therapy invented at Seattle Children’s was never approved for kids. Now the hospital is launching its own pediatric CAR-T startup

Lei Lei Wu

News Reporter

In 2021, the FDA approved Bristol Myers Squibb’s Breyanzi for some adult lymphoma patients, making it the third CAR-T therapy to become commercially available. …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

A CAR-T therapy invented at Seattle Children’s was never approved for kids. Now the hospital is launching its own pediatric CAR-T startup

Lei Lei Wu

News Reporter

Sign up to read this article for free.

Director Oligonucleotide R&D

Bachem

Bubendorf, BL, Switzerland

Bluebird bio to sell to investment funds after struggling to make money from gene therapies

CBER's deputy director departs as staff shakeup continues

Eli Lilly stockpiles $548M of oral weight loss drug ahead of launch

Will CRISPR matter?

FDA approves first drug to treat ultra-rare lipid storage disease

Trusted protection: Why the current meningococcal vaccination schedule shouldn’t change without strong evidence

A CAR-T ther­a­py in­vent­ed at Seat­tle Chil­dren’s was nev­er ap­proved for kids. Now the hos­pi­tal is launch­ing its own pe­di­atric CAR-T start­up

News Reporter

Sign up to read this article for free.

Bachem

Bubendorf, BL, Switzerland

A CAR-T therapy invented at Seattle Children’s was never approved for kids. Now the hospital is launching its own pediatric CAR-T startup